HSK55718

HSK55718 is a selective kappa opioid receptor (KOR) agonist developed for the management of postoperative pain. Developed by Haisco Pharmaceutical Group, it is designed to provide effective analgesia while potentially avoiding the common side effects associated with mu-opioid receptor agonists, such as respiratory depression, constipation, and high potential for abuse. The drug is administered via intravenous injection. Clinical trials, including Phase II studies led by investigators such as Yingyong Zhou, have evaluated its efficacy and safety in patients undergoing abdominal surgery, comparing it to standard treatments like morphine and placebo.